Samsung Bioepis succeeded in partially invalidating the 'Solaris patent. A blue light has been turned on for the release of the Soliris biosimilar this year. According to the pharmaceutical industry on the 13th, the Korean Intellectual Property Tribunal ruled in favor of Samsung Bioepis and ruled in favor of Samsung Bioepis in the invalidation trial filed in the Soliris usage patent.

Soliris is a rare disease treatment developed by Alexion in the U.S. It is known to be an ultra-high-priced drug with an annual drug cost of 500 million won. Handok is in charge of sales in Korea. In January 2010, PNH was approved in Korea as an indication. Since then, the indications have expanded to the atypical uremic sy